Atypical Depression Clinical Trial
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.
Status | Completed |
Enrollment | 201 |
Est. completion date | November 2004 |
Est. primary completion date | November 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Main Inclusion Criteria: - Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months - Female and male Caucasians aged 18 to 70 years - At least one of HAMD-28 scale items 22-26 scores >1 |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cassella-med GmbH & Co. KG |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00610506 -
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
|
Phase 3 | |
Completed |
NCT00296699 -
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression
|
Phase 4 | |
Completed |
NCT00215176 -
Modafinil for Atypical Depression
|
Phase 2/Phase 3 | |
Completed |
NCT00477854 -
Effects of Chromium Picolinate on Food Intake
|
N/A |